IV. Initial treatment of multiple myeloma

Hematological Oncology

Volumn 31, Issue SUPPL 2, 2013, Pages 33-37

  Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Myeloma; Prognosis; Therapy; Transplantation

Indexed keywords

ACETYLSALICYLIC ACID; BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PLERIXAFOR; PREDNISONE; THALIDOMIDE; VINCRISTINE; WARFARIN;

ACUTE KIDNEY FAILURE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CLINICAL PRACTICE; DRUG COST; EXTRAMEDULLARY DISEASE; HEALTH CARE QUALITY; HUMAN; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; OVERALL SURVIVAL; PLASMA CELL LEUKEMIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; STRATIFIED SAMPLE; THROMBOSIS; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MULTIPLE MYELOMA; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84879395871     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.2064     Document Type: Article

References (15)

1. Rajkumar SV. Treatment of multiple myeloma. Nature Rev Clin Oncol 2011; 8: 479-491.
2. Rajkumar SV, Gahrton G, Bergsagel PL. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011 Sep 22; 118: 3205-3211.
3. Rajkumar SV. Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 225-235.
4. Kumar S, Fonseca R, Ketterling RP, et al. Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics. Blood 2012 Mar 1; 119: 2100-2105.
5. Haessler J, Shaughnessy JD, Jr., Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007 December 1, 2007; 13: 7073-7079.
6. Rajkumar SV, Blood E, Vesole DH, et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431-436.
7. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37.
8. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol 2010 Sep 7; 28: 4621-4629.
9. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 April 12, 2010; 116: 679-686.
10. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet 2010 Dec 18; 376: 2075-2085.
11. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood 2011 Nov 24; 118: 5752-5758.
12. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood 2012 Mar 15; 119: 4375-4382.
13. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370: 1209-1218.
14. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 August 28, 2008; 359: 906-917.
15. Harousseau J, Attal M, Leleu X, et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.